ВЗАИМОСВЯЗЬ МЕЖДУ УРОВНЕМ ТИРЕОТРОПНОГО ГОРМОНА И РАКОМ ЩИТОВИДНОЙ ЖЕЛЕЗЫ

Черненко Е. В.

ОБЗОРЫ ЛИТЕРАТУРЫ

Научная статья.

Обзор посвящен анализу роли оценки уровня тиреотропного гормона (ТТГ) в диагностике, прогнозировании и предикции развития дифференцированного рака щитовидной железы (ЩЖ), особенно папиллярной карциномы. Большая часть исследований свидетельствует о том, что повышение уровня ТТГ ассоциировано с развитием папиллярного рака ЩЗ и его неблагоприятным прогнозом, связанным с повышением инвазивности и метастазирования. В то же время есть роботы, в которых не было выявлено связи между ТТГ и течением рака ЩЖ. Более того, увеличивается количество исследований, которые демонстрируют обратную связь между уровнем ТТГ и развитием и прогрессированием папиллярной карциномы ЩЖ. Такие противоречия могут быть связаны с разным размером и характеристиками исследуемых групп пациентов, дизайном исследований и действием других факторов, что могут влиять на уровень ТТГ, а именно возраста, наличия неопухолевых автономных узлов ЩЖ, аутоиммунного тиреоидита в том числе.

рак щитовидной железы, тиреотропный гормон

1. Hegedus L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goiter: current status and future perspectives. Endocr Rev. 2003;24(1):102-32. DOI: 10.1210/er.2002-0016
2. Liu FC, Lin HT, Lin SF, Kuo CF, Chung TT, Yu HP. Nationwide cohort study on the epidemiology and survival outcomes of thyroid cancer. Oncotarget. 2017;8(45):78429-51. DOI: 10.18632/oncotarget.19488
3. Shi LL, DeSantis C, Jemal A, Chen AY. Changes in thyroid cancer incidence, post-2009 American Thyroid Association guidelines. Laryngoscope. 2017;127(10):2437-41. DOI: 10.1002/lary.26473
4. American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133. DOI: 10.1089/thy.2015.0020
5. Hyeong SA, Hyun JK, Kyoung HK, Lee YS, Han SJ, Kim Y, et al. Thyroid Cancer Screening in South Korea Increases Detection of Papillary Cancers with No Impact on Other Subtypes or Thyroid Cancer Mortality. Тhyroid, 2016;26(11):1535-40. DOI: 10.1089/thy.2016.0075
6. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 2011;61:69-90. DOI: 10.3322/caac.20107
7. Amendoeira I, Maia T, Sobrinho-Simões M. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Endocr Relat Cancer. 2018;25(4):R247-R58. DOI: 10.1530/ERC-17-0513
8. Sulaieva O, Belemets N, Selezniov O, Chuba VYa, Shapochka DA, Chernenko EV. Histological and molecular diagnostics of thyroid tumors in line with international guidelines and recommendations. Clin Endocrinol. Endocr. Surg. 2018;1(61):7-14. DOI: https://doi.org/10.24026/18181384.1(61).2018.126898
9. Thompson LD. Ninety-four cases of encapsulated follicular variant of papillary thyroid carcinoma: A name change to Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features would help prevent overtreatment. Mod Pathol. 2016;29(7):698-707. DOI: 10.1038/ modpathol.2016.65
10. Lin JD, Hsueh C, Huang BY. Papillary thyroid carcinoma with different histological patterns. Chang Gung Med. J. 2011;34(1):23-34.
11. Nabhan F, Ringel MD. Thyroid nodules and cancer management guidelines: comparisons and controversies. Endocr. Relat. Cancer. 2017;24(2):R13-R26. DOI: 10.1530/ERC-16-0432
12. 8th Edition AJCC Cancer Staging Manual. Available from: https://cancerstaging.org/CSE/general/Pages/articles.aspx
13. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133. DOI: 10.1089/thy.2015.0020
14. Ying W, Xinrong Zh, Siyue L. Novel and Practical Scoring Systems for the Diagnosis of Thyroid Nodules. PLoS One. 2016;11(9). DOI: 10.1371/ journal.pone.0163039
15. Nikiforov YE, Ohori NP, Hodak SP, Carty SE, LeBeau SO, Ferris RL, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011;96(11):3390-7. DOI: 10.1210/jc.2011-1469
16. Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013;381(9871):105869. DOI: 10.1016/S0140-6736(13)60109-9
17. Golbert L, Cristo AP, Faccin CS. Serum TSH levels as a predictor of malignancy in thyroid nodules: a prospective study. PLoS One. 2017;12(11):e0188123. DOI: 10.1371/journal.pone.0188123
18. Spencer CA. Thyroid function tests: assay of thyroid hormones and related substances. Thyroid Disease Manager. 2017. Available from: http:// www.thyroidmanager.org/chapter/assay-of-thyroid-hormones-and-related-substances3/
19. Sheehan MT. Biochemical testing of the thyroid: TSH is the best and, oftentimes, only test needed – a review for primary care. Clin Med Res. 2016;14:83-92. DOI: 10.3389/fendo.2016.00142
20. Pearce SHS, Brabant G, Duntas LH, Monzani F, Peeters RP, Razvi S, et al. 2013 ETA guideline: management of subclinical hypothyroidism. Eur Thyroid J. 2013;2:215-28. DOI: 10.1159/000356507
21. Boelaert K, Horacek J, HolderRL, Watkinson JC, Sheppard MC, Franklyn JA. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. Journal of Clinical Endocrinology and Metabolism. 2006;91(11):4295-301. DOI: 10.1210/jc.2006-0527
22. Haymart MR, Repplinger DJ, Leverson GE. Higher serum TSH level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab. 2007;93:809-14. DOI: 10.1210/jc.2007-2215
23. Duccini K, Souza M, Delfim R. High Serum Thyrotropin Concentrations Within the Reference Range: A Predictor of Malignancy in Nodular Thyroid Disease. Med Princ Pract. 2018;27(3):272-7. DOI: 10.1159/000488196
24. Yazici P, Mihmanli M, Bozkurt E, Ozturk FY, Uludag M. Which is the best predictor of thyroid cancer: thyrotropin, thyroglobulin or their ratio? Hormones (Athens). 2016;15(2):256-63. DOI: 10.14310/horm.2002.1677
25. Rinaldi S. Thyroid-Stimulating Hormone, Thyroglobulin, and Thyroid Hormones and Risk of Differentiated Thyroid Carcinoma: The EPIC Study. JNCI: J Nat Cancer Institute. 2014;106(6):2014.
26. Sulem GP, Gudbjartsson D, Gudbjartsson DF, Jonasson JG, Masson G, He H, et al. Discovery of common variants associated with low TSH levels and thyroid cancer risk. Nat Genet. 2012;44(3):319-22. DOI: 10.1038/ng.1046
27. Derwahl M, Broecker M. Clinical review 101: thyrotropin may not be the dominant growth factor in benign and malignant thyroid tumors. J Clin Endocrinol Metab. 1999;84:829-34. DOI: 10.1210/jc.2007-2215
28. Mazzaferri EL. 2000 Thyroid cancer and Graves’ disease: the controversy ten years later. Endocrine Practice. 2000;6:221-5. DOI: 10.1210/ jc.2007-2215
29. Dailey ME, Lindsay S, Skahen R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. A.M.A. Archives of Surgery. 1955;70:291-7. DOI: 10.1001/archsurg.1955.01270080137023

«Вестник проблем биологии и медицины» Выпуск 4 Том 2 (147), 2018 год, 84-88 страницы, код УДК 616.018.72:616.441-006.6-037

10.29254/2077-4214-2018-4-2-147-84-88